Azelastine Nasal Spray Shows Promise in Preventing COVID-19 and Other respiratory Infections
Table of Contents
A new study suggests that a common allergy medication, azelastine nasal spray, may offer a readily available defence against SARS-CoV-2 and a range of other respiratory viruses. The findings, published following a rigorous clinical trial, could represent a important step forward in preventative healthcare.
A research group from Saarland University Hospital conducted a randomized, double-blind, placebo-controlled phase II study involving 450 healthy adults between March 2023 and July 2024. The research was spurred by earlier laboratory findings demonstrating azelastine’s antiviral activity against various respiratory viruses,including the virus that causes COVID-19. Researchers aimed to determine if these in vitro results translated to real-world effectiveness.
significant Reduction in COVID-19 Infections
The study participants were divided into two groups: one receiving azelastine nasal spray (0.1%) three times daily for 56 days, and a control group receiving a placebo. Throughout the study period, participants underwent twice-weekly rapid tests, with positive results confirmed by PCR testing for SARS-CoV-2. Individuals experiencing symptoms but testing negative for COVID-19 were further evaluated using multiplex PCR testing to identify other respiratory viruses.
the primary measure of success was the number of confirmed SARS-CoV-2 infections. An intention-to-treat (ITT) analysis revealed a significantly lower incidence of PCR-confirmed COVID-19 infections in the group treated with azelastine compared to the placebo group. Specifically, just 5 infections occurred in the azelastine arm, versus 15 in the placebo arm – a difference of 2.2% versus 6.7% (Odds Ratio,0.31).
Furthermore, the time until infection was notably longer in the azelastine group, averaging 31 days compared to 19 days in the placebo group. The nasal spray also demonstrably reduced the number of symptomatic COVID-19 infections,with a rate of 1.8% in the azelastine group compared to 6.3% in the placebo group.
Broad-Spectrum Respiratory protection
the benefits of azelastine extended beyond COVID-19. The study also observed a reduction in infections caused by other respiratory pathogens,most notably rhinoviruses – the common cold. Rhinovirus infections occurred less frequently in the azelastine group (1.8% vs. 6.3%). participants receiving azelastine experienced fewer laboratory-confirmed infections, regardless of the viral cause, which correlated with a decrease in self-reported sick days.
safety and tolerability
the safety profile of azelastine nasal spray remained consistent with its established use in allergy treatment. Participants reported a slightly more frequent experience of a bitter taste and minor nosebleeds, but serious side effects were rare and not linked to the treatment.
Limitations and Future Research
While promising, the study authors acknowledge several limitations. The sample size was relatively small, the overall number of infections was low, and the research was conducted at a single center. Additionally, the distinctive taste of the nasal spray may have partially compromised the blinding process.
Crucially, nearly all participants were vaccinated, raising questions about azelastine’s effectiveness in unvaccinated or immunocompromised individuals. The authors strongly recommend larger, multicenter studies to assess the spray’s efficacy across diverse populations and against a wider range of pathogens.
These findings suggest that azelastine nasal spray could be a safe and accessible tool for reducing the risk of infection from SARS-CoV-2 and other common respiratory viruses, notably rhinoviruses, but further research is needed to fully understand its potential.
